Sorry, you need to enable JavaScript to visit this website.

Welcome to Integrated Oncology

Home Page - Slider

Working with Integrated Oncology
Oncology Testing
VistaSeq Hereditary Cancer Testing
For Patients
working with integrated oncology
Working with Integrated Oncology

More than 25 years of testing experience and expertise

Oncology Testing

Evolving personalize testing for you

vistaseq
VistaSeq Hereditary Cancer Testing

Because Knowledge is a Powerful Tool

for patients
For Patients

Dedicated to helping educate patients and inform the public about oncology diagnostic testing.

For Patients

Prepare for visits with your doctor or a genetic counselor by learning about testing.

Working with Integrated Oncology

Integrated Oncology Highlights

Every patient comes from a different background with a unique personal and family history. Patients with a family history that is specific to one cancer type may receive more benefit from a focused hereditary panel test. Integrated Oncology offers several cancer panel options for a more targeted approach to testing.  Click here to view the press release.

Integrated Oncology now offers the FDA-approved cobas EGFR mutation test V2 in both FFPE tissue and plasma samples

This test was recently FDA-approved as a complementary diagnostic assay that may help identify patients with locally advanced or metastatic urothelial carcinoma more likely to respond to treatment with TecentriqTM(atezolizumab).

This test was recently FDA approved as a companion diagnostic assay to aid in identifying metastatic NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). 

This test was recently FDA-approved as a complementary diagnostic test to help physicians determine which patients may benefit most with OPDIVO® (nivolumab). 

Prosigna Breast Cancer Prognostic Gene Signature Assay, which is based on the PAM50 gene signature, is an FDA 510(k) cleared assay to assess a patient’s risk of distant recurrence of disease. 

IntelliGEN® Oncology Therapeutic Panel (NGS) assay provides an assessment of targetable mutations within a panel of cancer genes known to be involved in the development, progression and/or treatment of cancers.